Literature DB >> 17142835

Peptides derived from the C2 domain of protein kinase C epsilon (epsilon PKC) modulate epsilon PKC activity and identify potential protein-protein interaction surfaces.

Relly Brandman1, Marie-Hélène Disatnik, Eric Churchill, Daria Mochly-Rosen.   

Abstract

Peptides derived from protein kinase C (PKC) modulate its activity by interfering with critical protein-protein interactions within PKC and between PKC and PKC-binding proteins (Souroujon, M. C., and Mochly-Rosen, D. (1998) Nat. Biotechnol. 16, 919-924). We previously demonstrated that the C2 domain of PKC plays a critical role in these interactions. By focusing on epsilonPKC and using a rational approach, we then identified one C2-derived peptide that acts as an isozyme-selective activator and another that acts as a selective inhibitor of epsilonPKC. These peptides were used to identify the role of epsilonPKC in protection from cardiac and brain ischemic damage, in prevention of complications from diabetes, in reducing pain, and in protecting transplanted hearts. The efficacy of these two peptides led us to search for additional C2-derived peptides with PKC-modulating activities. Here we report on the activity of a series of 5-9-residue peptides that are derived from regions that span the length of the C2 domain of epsilonPKC. These peptides were tested for their effect on PKC activity in cells in vivo and in an ex vivo model of acute ischemic heart disease. Most of the peptides acted as activators of PKC, and a few peptides acted as inhibitors. PKC-dependent myristoylated alanine-rich C kinase substrate phosphorylation in epsilonPKC knock-out cells revealed that only a subset of the peptides were selective for epsilonPKC over other PKC isozymes. These epsilonPKC-selective peptides were also protective of the myocardium from ischemic injury, an epsilonPKC-dependent function (Liu, G. S., Cohen, M. V., Mochly-Rosen, D., and Downey, J. M. (1999) J. Mol. Cell. Cardiol. 31, 1937-1948), and caused selective translocation of epsilonPKC over other isozymes when injected systemically into mice. Examination of the structure of the C2 domain from epsilonPKC revealed that peptides with similar activities clustered into discrete regions within the domain. We propose that these regions represent surfaces of protein-protein interactions within epsilonPKC and/or between epsilonPKC and other partner proteins; some of these interactions are unique to epsilonPKC, and others are common to other PKC isozymes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142835     DOI: 10.1074/jbc.M608521200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

Review 1.  Rationally designed peptide regulators of protein kinase C.

Authors:  Eric N Churchill; Nir Qvit; Daria Mochly-Rosen
Journal:  Trends Endocrinol Metab       Date:  2008-12-04       Impact factor: 12.015

Review 2.  The life and death of protein kinase C.

Authors:  Christine M Gould; Alexandra C Newton
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

Review 3.  Structural basis of protein kinase C isoform function.

Authors:  Susan F Steinberg
Journal:  Physiol Rev       Date:  2008-10       Impact factor: 37.312

4.  Mast cells and epsilonPKC: a role in cardiac remodeling in hypertension-induced heart failure.

Authors:  Suresh Selvaraj Palaniyandi; Koichi Inagaki; Daria Mochly-Rosen
Journal:  J Mol Cell Cardiol       Date:  2008-09-04       Impact factor: 5.000

5.  Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer.

Authors:  Liwei Bao; Michael A Gorin; Manchao Zhang; Alejandra C Ventura; William C Pomerantz; Sofia D Merajver; Theodoros N Teknos; Anna K Mapp; Quintin Pan
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

6.  Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.

Authors:  E Masselli; C Carubbi; G Gobbi; P Mirandola; D Galli; S Martini; S Bonomini; M Crugnola; L Craviotto; F Aversa; M Vitale
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

7.  Fluvastatin inhibits Rab5-mediated IKs internalization caused by chronic Ca2+-dependent PKC activation.

Authors:  Xiaorong Xu Parks; Elsa Ronzier; Jin O-Uchi; Coeli M Lopes
Journal:  J Mol Cell Cardiol       Date:  2019-03-18       Impact factor: 5.000

8.  PKCε as a novel promoter of skeletal muscle differentiation and regeneration.

Authors:  D Di Marcantonio; D Galli; C Carubbi; G Gobbi; V Queirolo; S Martini; S Merighi; M Vaccarezza; N Maffulli; S M Sykes; M Vitale; P Mirandola
Journal:  Exp Cell Res       Date:  2015-09-30       Impact factor: 3.905

9.  Interleukin-1β reduces L-type Ca2+ current through protein kinase Cϵ activation in mouse heart.

Authors:  Nabil El Khoury; Sophie Mathieu; Céline Fiset
Journal:  J Biol Chem       Date:  2014-06-16       Impact factor: 5.157

10.  Phosphorylation of zona occludens-2 by protein kinase C epsilon regulates its nuclear exportation.

Authors:  David Chamorro; Lourdes Alarcón; Arturo Ponce; Rocio Tapia; Héctor González-Aguilar; Martha Robles-Flores; Teresa Mejía-Castillo; José Segovia; Yamir Bandala; Eusebio Juaristi; Lorenza González-Mariscal
Journal:  Mol Biol Cell       Date:  2009-07-22       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.